Portada›Jueves 9 de octubre de 2025

Biomédicas del NASDAQ ante la SEC, jueves 9 de octubre de 2025

Los 28 documentos que 23 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← miércoles 8 de octubre de 2025 · viernes 10 de octubre de 2025 →

¿Lo quieres en tu correo cada mañana, y solo de tus empresas? Crear una cuenta.

Emisiones y dilución

1. BIAFbioAffinity Technologies, Inc.424B5Nueva emisión de acciones con precioEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …than in the normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment. We have determined that our current liquidity position raises substantial doubt about our ability to continue as a going concern. 7 We have a limited operating history, which makes it difficult to evaluate our current business and future prospects. We are a company with limited operating history, and our operations are subject…
2. TTRXTurn Therapeutics Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …development. We expect to incur additional losses for the foreseeable future, and it is possible we may never achieve or maintain profitability. Our consolidated financial statements therefore express substantial doubt about our ability to continue as a going concern. ​ • We have a limited operating history and there are inherent uncertainties and risks in pharmaceutical and medical device product development and commercialization. ​ • If we fail to obtain or generate…

   En el documentoDebilidad material en el control internotexto original ▸

   …that competes against large, well-established companies with long-standing relationships, extensive clinical data, and recognized brands, as well as against new companies with innovative products. ​ • We identified a material weakness in our internal control over the accuracy of our financial reporting. Any failure to maintain an effective control over financial reporting may result in material misstatements of our consolidated financial…
3. TLRYTilray Brands, Inc.S-3ASRCapacidad de emisión registradaEDGAR

Participaciones y control

1. DMRADamora Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
2. SPRBSPRUCE BIOSCIENCES, INC.SC 13D/ACambio en participación significativaEDGAR
3. ZBIOZenas BioPharma, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. ALZNAlzamend Neuro, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
2. BFRGBullFrog AI Holdings, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
3. CDTCDT Equity Inc.8-KCambio de estatutosEDGAR
   En el documentoContrasplit de accionestexto original ▸

   …Announces Reverse Stock Split NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 9, 2025 (GLOBE NEWSWIRE) – CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-8 reverse stock split of the Company’s common stock. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios, at the…
4. CYPHCYPHERPUNK TECHNOLOGIES INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
5. AARDAardvark Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
   En el documentoDesignación de medicamento huérfanotexto original ▸

   …activates gut-brain neurologic signaling to mediate hunger. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. The FDA has granted ARD-101 both Orphan Drug Designation and Rare Pediatric Disease Designation for PWS. ARD-101 is being evaluated in the Phase 3 HERO trial for hyperphagia associated with PWS. About Aardvark Therapeutics, Inc. Aardvark is a clinical-stage…
6. AGENAGENUS INC8-KNuevo acuerdo materialEDGAR
7. BIAFbioAffinity Technologies, Inc.8-KNuevo acuerdo materialEDGAR
8. CABACabaletta Bio, Inc.8-KOtros hechos relevantesEDGAR
9. EDITEditas Medicine, Inc.8-KOtros hechos relevantesEDGAR
10. GANXGain Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
11. MNKDMANNKIND CORP8-KNuevo acuerdo materialEDGAR
12. NEOGNEOGEN CORP8-KResultadosEDGAR
13. NEOGNEOGEN CORP10-QInforme trimestralEDGAR
14. NRIXNurix Therapeutics, Inc.8-KResultadosEDGAR
15. NRIXNurix Therapeutics, Inc.10-QInforme trimestralEDGAR
16. NTHINEONC TECHNOLOGIES HOLDINGS, INC.8-KNuevo acuerdo materialEDGAR
17. ONMDOneMedNet Corp8-KOtros hechos relevantesEDGAR
18. PALIPALISADE BIO, INC.8-KOtros hechos relevantesEDGAR
19. RNTXRein Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de medicamento huérfanotexto original ▸

    …indications. Rein’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S.. Rein’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan…
20. TLRYTilray Brands, Inc.8-KResultadosEDGAR
21. TLRYTilray Brands, Inc.10-QInforme trimestralEDGAR
22. TSHATaysha Gene Therapies, Inc.8-KOtros hechos relevantesEDGAR

← miércoles 8 de octubre de 2025 · viernes 10 de octubre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.